NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Tuesday reported positive
results from a second interim analysis of the Phase 3 CARTITUDE-4 study
evaluating Carvykti compared to standard therapies for the treatment of patients
with relapsed or lenalidomide-refractory multiple myeloma after one prior line
of therapy.

Results from the interim analysis showed a statistically significant and
clinically meaningful improvement in overall survival (OS) for patients treated
with Carvykti versus standard therapies, the company said in a statement.
Further, safety data were consistent with the approved label.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX